Industry: Treatment for lung infections
NXT Biologics develops next-generation therapeutics for lung infections and respiratory illnesses. The company’s innovations arose from new insights into the mechanisms of these diseases, discovered by researchers at the University of Georgia.
One such disease is pneumocystis pneumonia, a fungal disease that severely affects immunocompromised people. NXT Biologics has patented a vaccine for this illness. The vaccine uses recombinant proteins that boost immunity to the fungus. It is undergoing further testing.
NXT Biologics is also developing diagnostics for pneumocystis pneumonia and therapeutic monoclonal antibodies to treat people with fungal lung infections.